| Christopher Jay Reynolds, MD | |
|
52 N 1100 E, American Fork, UT 84003-2952 | |
| (801) 763-0901 | |
| (801) 763-0903 |
| Full Name | Christopher Jay Reynolds |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 42 Years |
| Location | 52 N 1100 E, American Fork, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700843695 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| American Fork Hospital | American fork, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Neurological Associates Llc | 1153306360 | 2 |
News Archive
Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and six months ended June 30, 2011 and provided a business update.
› Verified 5 days ago
| Entity Name | Neurological Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912963372 PECOS PAC ID: 1153306360 Enrollment ID: O20040825000281 |
News Archive
Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and six months ended June 30, 2011 and provided a business update.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Jay Reynolds, MD 52 N 1100 E, American Fork, UT 84003-2952 Ph: (801) 763-0901 | Christopher Jay Reynolds, MD 52 N 1100 E, American Fork, UT 84003-2952 Ph: (801) 763-0901 |
News Archive
Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and six months ended June 30, 2011 and provided a business update.
› Verified 5 days ago
Ludmil K Manov, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 21 N 490 W, American Fork, UT 84003 Phone: 801-642-2396 Fax: 801-642-2496 | |
Dr. Thu A Nguyen, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1175 E 50 S, Suite 161, American Fork, UT 84003 Phone: 801-492-5992 Fax: 801-812-5439 | |
Dr. Mohammad Entezari Taher, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 212 S 1100 E, American Fork, UT 84003 Phone: 801-763-0901 Fax: 801-763-0903 |